R1	Has_value Arg1:T2 Arg2:T3	
*	OR T4 T5
R2	Has_qualifier Arg1:T8 Arg2:T7	
R3	Has_multiplier Arg1:T9 Arg2:T10	
*	OR T14 T13 T12 T11
R4	Subsumes Arg1:T17 Arg2:T14	
R5	Has_context Arg1:T8 Arg2:T9	
R6	Has_qualifier Arg1:T8 Arg2:T17	
R7	Subsumes Arg1:T18 Arg2:T19	
R8	Has_index Arg1:T28 Arg2:T29	
R9	Has_qualifier Arg1:T26 Arg2:T27	
R10	Has_negation Arg1:T26 Arg2:T25	
R11	Subsumes Arg1:T23 Arg2:T24	
R12	Subsumes Arg1:T21 Arg2:T22	
R13	Subsumes Arg1:T20 Arg2:T21	
*	OR T21 T23
R14	Has_temporal Arg1:T20 Arg2:T28	
R15	Has_qualifier Arg1:T33 Arg2:T34	
R16	Has_context Arg1:T33 Arg2:T32	
R17	Has_value Arg1:T32 Arg2:T35	
R18	AND Arg1:T33 Arg2:T36	
R19	Has_qualifier Arg1:T39 Arg2:T34	
R20	Has_context Arg1:T39 Arg2:T40	
R21	Has_value Arg1:T40 Arg2:T38	
R22	AND Arg1:T39 Arg2:T37	
*	OR T39 T33
R24	Has_value Arg1:T43 Arg2:T44	
R27	Has_index Arg1:T49 Arg2:T50	
R28	multi Arg1:T50 Arg2:T51	
R23	Subsumes Arg1:T43 Arg2:T46	
R25	multi Arg1:T43 Arg2:T42	
R26	Has_qualifier Arg1:T41 Arg2:T45	
R29	Has_temporal Arg1:T47 Arg2:T49	
R30	Has_value Arg1:T47 Arg2:T48	
R31	multi Arg1:T63 Arg2:T64	
R32	Has_index Arg1:T62 Arg2:T63	
R33	Has_multiplier Arg1:T60 Arg2:T61	
R34	Has_temporal Arg1:T60 Arg2:T62	
R35	Has_multiplier Arg1:T56 Arg2:T57	
R36	Has_multiplier Arg1:T56 Arg2:T58	
R37	Has_temporal Arg1:T56 Arg2:T59	
R38	Has_multiplier Arg1:T52 Arg2:T53	
R39	Has_multiplier Arg1:T52 Arg2:T54	
R40	Has_temporal Arg1:T52 Arg2:T55	
*	OR T52 T56
R41	Subsumes Arg1:T66 Arg2:T67	
R42	multi Arg1:T78 Arg2:T79	
R43	Has_index Arg1:T77 Arg2:T78	
R44	Has_multiplier Arg1:T75 Arg2:T76	
R45	Has_temporal Arg1:T75 Arg2:T77	
R46	Has_multiplier Arg1:T71 Arg2:T72	
R47	Has_multiplier Arg1:T71 Arg2:T73	
R48	Has_temporal Arg1:T71 Arg2:T74	
R49	Has_multiplier Arg1:T66 Arg2:T68	
R50	Has_multiplier Arg1:T66 Arg2:T69	
R51	Has_temporal Arg1:T66 Arg2:T70	
*	OR T66 T71
T1	Post-eligibility 0 144	Provision of written informed consent (by patient or appropriate designee according to local regulations) prior to any study specific procedures
T2	Person 147 151	Aged
T3	Value 152 169	18 years or older
T4	Person 171 175	male
T5	Person 179 185	female
T6	Condition 199 221	stable angina pectoris
T7	Qualifier 227 248	angiographic evidence
T8	Condition 252 255	CAD
T9	Observation 257 274	diameter stenosis
T10	Multiplier 275 280	= 50%
T11	Qualifier 356 379	right coronary arteries
T12	Qualifier 335 350;362 379	left circumflex coronary arteries
T13	Qualifier 309 333;362 379	left anterior descending coronary arteries
T14	Qualifier 298 307;362 379	left main coronary arteries
T15	Non-query-able 352 355	and
T17	Qualifier 285 290;362 379	major coronary arteries
T18	Condition 402 423	myocardial infarction
T19	Condition 425 427	MI
T20	Procedure 441 467	coronary revascularization
T21	Procedure 475 509	percutaneous coronary intervention
T22	Procedure 511 514	PCI
T23	Procedure 519 547	coronary artery bypass graft
T24	Procedure 549 553	CABG
T25	Negation 556 559	not
T26	Procedure 583 586	PCI
T27	Qualifier 574 582	elective
T28	Temporal 587 619	during the index hospitalization
T29	Reference_point 598 619	index hospitalization
T31	Condition 643 667	type 2 diabetes mellitus
T32	Observation 670 712	Post-procedural residual diameter stenosis
T33	Condition 728 735	lesions
T34	Qualifier 720 727	treated
T35	Value 736 741	< 20%
T36	Procedure 759 777	stent implantation
T37	Procedure 801 820	balloon angioplasty
T38	Value 781 786	< 50%
T39	Condition 728 735	lesions
T40	Observation 670 712	Post-procedural residual diameter stenosis
T41	Condition 822 850	Post-procedural thrombolysis
T42	Condition 854 875	myocardial infarction
T43	Measurement 854 875;883 888	myocardial infarction grade
T44	Value 889 890	3
T45	Qualifier 899 914	treated vessels
T47	Measurement 925 946	cardiac troponin test
T48	Value 916 924	Negative
T49	Temporal 947 977	before the index elective PCI.
T50	Reference_point 958 976	index elective PCI
T51	Procedure 973 976	PCI
T46	Measurement 877 881	TIMI
T52	Drug 986 997	Clopidogrel
T53	Multiplier 998 1003	75 mg
T54	Multiplier 1004 1009	daily
T55	Temporal 1015 1034	for at least 7 days
T56	Drug 1045 1056	Clopidogrel
T57	Multiplier 1057 1062	75 mg
T58	Multiplier 1063 1068	daily
T59	Temporal 1074 1094	for less than 7 days
T60	Drug 1118 1129	Clopidogrel
T61	Multiplier 1104 1117	300 to 600 mg
T62	Temporal 1143 1153	before PCI
T63	Reference_point 1150 1153	PCI
T64	Procedure 1150 1153	PCI
T66	Drug 1163 1183	acetylsalicylic acid
T67	Drug 1185 1188	ASA
T68	Multiplier 1190 1196	100 mg
T69	Multiplier 1197 1202	daily
T70	Temporal 1213 1232	for at least 7 days
T71	Drug 1243 1246	ASA
T72	Multiplier 1247 1253	100 mg
T73	Multiplier 1254 1259	daily
T74	Temporal 1265 1285	for less than 7 days
T75	Drug 1302 1305	ASA
T76	Multiplier 1295 1301	300 mg
T77	Temporal 1319 1329	before PCI
T78	Reference_point 1326 1329	PCI
T79	Procedure 1326 1329	PCI
T81	Pregnancy_considerations 1332 1418	have a negative urine or blood pregnancy test at enrolment and prior to randomization;
T82	Pregnancy_considerations 1420 1663	currently be using a hormonal contraceptive and agree to continue its use in addition to using double-barrier local contraception (i.e., intra-uterine device plus spermicidal and condom for male partner) from screening through study completion
